This is not the most recent version of the article. View current version (9 OCT 2014)

Intervention Review

You have free access to this content

Antibiotics for community acquired pneumonia in adult outpatients

  1. Lise M Bjerre1,*,
  2. Theo JM Verheij2,
  3. Michael M Kochen1

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 6 JUL 2009

DOI: 10.1002/14651858.CD002109.pub3


How to Cite

Bjerre LM, Verheij TJM, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD002109. DOI: 10.1002/14651858.CD002109.pub3.

Author Information

  1. 1

    University of Göttingen, Department of General Practice/Family Medicine, Göttingen, Germany

  2. 2

    University Medical Center Utrecht, Julius Center for General Practice and Patient-Oriented Research, Utrecht, Netherlands

*Lise M Bjerre, Department of General Practice/Family Medicine, University of Göttingen, Humboldtallee 38, Göttingen, D-37073, Germany. lbjerre@hotmail.com. lbjerre@gwdg.de.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 7 OCT 2009

SEARCH

This is not the most recent version of the article. View current version (09 OCT 2014)

[Figure 1]
Figure 1. Overview of included studies and antibiotic pairs studied. * indicates studies new to this review; shaded ovals indicate quinolones (gyrase inhibitors), white ovals indicate macrolides
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each methodological quality item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Erythromycin versus clarythromycin, Outcome 1 Clinical success.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Erythromycin versus clarythromycin, Outcome 2 Bacteriological success.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Erythromycin versus clarythromycin, Outcome 3 Radiological success.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Erythromycin versus clarythromycin, Outcome 4 Drug-related adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Azithromycin microspheres versus levofloxacin, Outcome 1 Clinical success.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Azithromycin microspheres versus levofloxacin, Outcome 2 Bacteriological success.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Azithromycin microspheres versus levofloxacin, Outcome 3 Drug-related adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Azithromycin microspheres versus clarithromycin, Outcome 1 Clinical success.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Azithromycin microspheres versus clarithromycin, Outcome 2 Bacteriological success.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Azithromycin microspheres versus clarithromycin, Outcome 3 Drug-related adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Telithromycin versus clarithromycin, Outcome 1 Clinical success.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Telithromycin versus clarithromycin, Outcome 2 Bacteriological success.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Telithromycin versus clarithromycin, Outcome 3 Drug-related adverse effects.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Telithromycin versus levofloxacin, Outcome 1 Clinical success.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Telithromycin versus levofloxacin, Outcome 2 Bacteriological success.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Telithromycin versus levofloxacin, Outcome 3 Clinical efficacy against H. influenzae.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Telithromycin versus levofloxacin, Outcome 4 Drug-related adverse effects.